American biotech firm that uses gene-editing to treat ultra-rare genetic disorders. Launched in early 2026 by Jennifer Doudna, Nobel-prizewinning pioneer of CRISPR gene-editing.
First Rule of History: History doesn't repeat itself -- historians merely repeat each other.